1. Home
  2. PLAY vs NTLA Comparison

PLAY vs NTLA Comparison

Compare PLAY & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dave & Buster's Entertainment Inc.

PLAY

Dave & Buster's Entertainment Inc.

HOLD

Current Price

$17.35

Market Cap

718.2M

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$9.24

Market Cap

986.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLAY
NTLA
Founded
1982
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
718.2M
986.9M
IPO Year
1995
2016

Fundamental Metrics

Financial Performance
Metric
PLAY
NTLA
Price
$17.35
$9.24
Analyst Decision
Buy
Buy
Analyst Count
7
22
Target Price
$26.86
$19.83
AVG Volume (30 Days)
1.5M
3.3M
Earning Date
12-09-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.01
N/A
Revenue
$2,107,700,000.00
$57,528,000.00
Revenue This Year
$1.89
$1.96
Revenue Next Year
$4.69
N/A
P/E Ratio
$1,969.84
N/A
Revenue Growth
N/A
33.52
52 Week Low
$13.04
$5.90
52 Week High
$35.53
$28.25

Technical Indicators

Market Signals
Indicator
PLAY
NTLA
Relative Strength Index (RSI) 51.91 44.93
Support Level $15.68 $8.94
Resistance Level $21.27 $9.62
Average True Range (ATR) 0.82 0.43
MACD -0.22 0.16
Stochastic Oscillator 29.86 44.14

Price Performance

Historical Comparison
PLAY
NTLA

About PLAY Dave & Buster's Entertainment Inc.

Dave & Buster's Entertainment Inc owns and operates nearly a hundred entertainment and dining establishments in the United States where customers can eat, drink, play games, and watch televised sports. Each store offers a full menu of entries and appetizers, a complete selection of alcoholic and non-alcoholic beverages, and an extensive assortment of entertainment attractions centered around playing games and watching live sports and other televised events. It derives maximum revenue from Entertainment.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: